---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-007259"
form_type: "8-K"
ticker: "ROIV"
cik: "0001635088"
company_name: "Roivant Sciences Ltd."
filed_at: "2024-02-13T23:59:59+00:00"
generated_at: "2026-06-06T03:26:49.154184+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Roivant posts $5.1B net income on $7.1B Telavant sale to Roche; cash at $6.7B

## Summary
- Net income $5.1B ($6.37 basic EPS) vs loss of $384.9M a year ago, driven by $5.3B gain on Telavant sale.
- Net cash proceeds from Telavant sale ~$5.2B; consolidated cash, cash equivalents and restricted cash $6.7B at Dec 31, 2023.
- VTAMA net product revenue $20.7M for Q3; over 300k prescriptions written by ~14k prescribers since launch.
- Batoclimab Phase 2 Graves' disease trial shows >50% response rate in initial cohort; additional data ongoing.
- Non-GAAP net loss $174.9M; R&D expenses $123.7M; SG&A $197.3M; RVT-2001 development discontinued.

## SEC filing metadata
- accession: 0001140361-24-007259
- form_type: 8-K
- ticker: ROIV
- cik: 0001635088
- company_name: Roivant Sciences Ltd.
- filed_at: 2024-02-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1635088/000114036124007259/0001140361-24-007259-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1635088/000114036124007259/ef20021494_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-007259
- JSON: https://secwatch.observer/filing/0001140361-24-007259.json
- Plain text: https://secwatch.observer/filing/0001140361-24-007259.txt

## Key facts
- Earnings Releases
  Roivant Sciences Ltd. reported financial results for the third quarter ended December 31, 2023.
  - Period: the third quarter ended December 31, 2023
  - Result: reported results
  source text: Roivant Sciences Ltd. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1635088/000114036124007259/0001140361-24-007259-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.